Please login to the form below

Not currently logged in
Email:
Password:

Karyopharm

This page shows the latest Karyopharm news and features for those working in and with pharma, biotech and healthcare.

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen cuts $217m deal for Karyopharm neurology drug

Biogen has agreed a deal to license a brain disease candidate from Karyopharm for $10m upfront, and up to $217m in milestone payments.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Option, licence. 223. Karyopharm Therapeutics/ Biogen. Oral SINE compound KPT-350 (IND ready) other assets for neurological and neurodegenerative conditions.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...